Your browser doesn't support javascript.
loading
Digitalization of adverse event management in oncology to improve treatment outcome-A prospective study protocol.
Kestler, Angelika M R; Kühlwein, Silke D; Kraus, Johann M; Schwab, Julian D; Szekely, Robin; Thiam, Patrick; Hühne, Rolf; Jahn, Niels; Fürstberger, Axel; Ikonomi, Nensi; Balig, Julien; Schuler, Rainer; Kuhn, Peter; Steger, Florian; Seufferlein, Thomas; Kestler, Hans A.
Afiliación
  • Kestler AMR; Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany.
  • Kühlwein SD; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Kraus JM; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Schwab JD; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Szekely R; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Thiam P; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Hühne R; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Jahn N; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Fürstberger A; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Ikonomi N; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Balig J; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Schuler R; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
  • Kuhn P; Comprehensive Cancer Center, University Hospital Ulm, Ulm, Germany.
  • Steger F; Institute of the History, Philosophy and Ethics of Medicine, Ulm University, Ulm, Germany.
  • Seufferlein T; Department of Internal Medicine I, University Hospital Ulm, Ulm, Germany.
  • Kestler HA; Institute of Medical Systems Biology, Ulm University, Ulm, Germany.
PLoS One ; 16(6): e0252493, 2021.
Article en En | MEDLINE | ID: mdl-34086740
ABSTRACT
The occurrence of adverse events frequently accompanies tumor treatments. Side effects should be detected and treated as soon as possible to maintain the best possible treatment outcome. Besides the standard reporting system Common Terminology Criteria for Adverse Events (CTCAE), physicians have recognized the potential of patient-reporting systems. These are based on a more subjective description of current patient reporting symptoms. Patient-reported symptoms are essential to define the impact of a given treatment on the quality of life and the patient's wellbeing. They also act against an underreporting of side effects which are paramount to define the actual value of a treatment for the individual patient. Here, we present a study protocol for a clinical trial that assesses the potential of a smartphone application for CTCAE conform symptom reporting and tracking that is adjusted to the standard clinical reporting system rather than symptom oriented descriptive trial tools. The presented study will be implemented in two parts, both lasting over six months. The first part will assess the feasibility of the application with 30 patients non-randomly divided into three equally-sized age groups (<55years, 55-75years, >75years). In the second part 36 other patients will be randomly assigned to two groups, one reporting using the smartphone and one not. This prospective second part will compare the impact of smartphone reported adverse events regarding applied therapy doses and quality of life to those of patients receiving standard care. We aim for early detection and treatment of adverse events in oncological treatment to improve patients' safety and outcomes. For this purpose, we will capture frequent adverse events of chemotherapies, immunotherapies, or other targeted therapies with our smartphone application. The presented trial is registered at the U.S. National Library of Medicine ClinicalTrials.gov (NCT04493450) on July 30, 2020.
Asunto(s)

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Telemedicina / Teléfono Inteligente / Inmunoterapia / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Screening_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Alemania

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Telemedicina / Teléfono Inteligente / Inmunoterapia / Neoplasias / Antineoplásicos Tipo de estudio: Clinical_trials / Guideline / Observational_studies / Screening_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: PLoS One Asunto de la revista: CIENCIA / MEDICINA Año: 2021 Tipo del documento: Article País de afiliación: Alemania